Literature DB >> 23102507

Experimental model for reproduction of canine visceral leishmaniosis by Leishmania infantum.

J Fernández-Cotrina1, V Iniesta, S Belinchón-Lorenzo, R Muñoz-Madrid, F Serrano, J C Parejo, L Gómez-Gordo, M Soto, C Alonso, L C Gómez-Nieto.   

Abstract

In this report an experimental model of Leishmania infantum (L. infantum) infection in dogs is described. The data presented are derived from an overall and comparative analysis of the clinical outcomes of three groups of dogs intravenously infected with 500,000 promastigotes on different dates (2003, 2006 and 2008). The parasites used for challenge were isolated from a dog having a patent form of leishmaniosis, classified as MCAN/ES/1996/BCN150 zymodeme MON-1. Late-log-phase promastigote forms derived from cultured amastigotes obtained from the spleen of the heavily infected hamsters were used for infection. Only one single infective dose was administered to each dog. After challenge, the animals were monitored for 12 months. To analyze the disease outcome, several biopathological, immunological and parasitological end-points were considered. The analysis of the infected dogs indicated that the development of the clinical disease was very similar in the three experimental challenges, as shown by the immune response, the parasite load and the clinical and histopathological lesions detected at necropsy. A high similarity was also observed between the disease development after the experimental challenge and the one reported to occur in endemic natural infection areas, as various degrees of susceptibility to the disease and even resistance were observed in the experimentally infected animals. We believe that this challenge model faithfully reproduces and mimics the course of a natural infection and that it could be used as a suitable tool for analyzing the efficacy of anti-Leishmania drugs and vaccines.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23102507     DOI: 10.1016/j.vetpar.2012.10.002

Source DB:  PubMed          Journal:  Vet Parasitol        ISSN: 0304-4017            Impact factor:   2.738


  14 in total

1.  Immunohistochemical study of renal fibropoiesis associated with dogs naturally and experimentally infected with two different strains of Leishmania (L.) infantum.

Authors:  Adriano F Alves; Ramon A Pereira; Helida M de Andrade; David M Mosser; Wagner L Tafuri
Journal:  Int J Exp Pathol       Date:  2019-11-06       Impact factor: 1.925

2.  Immunogenicity in dogs and protection against visceral leishmaniasis induced by a 14kDa Leishmania infantum recombinant polypeptide.

Authors:  Claudia Abeijon; Nada Daifalla; Greice Krautz-Peterson; Stefano Pizzirani; Gillian Beamer; Neuza M Frazatti-Gallina; Isaias Raw; Antonio Campos-Neto
Journal:  Trials Vaccinol       Date:  2016

3.  Effectiveness of the sesquiterpene (-)-α-bisabolol in dogs with naturally acquired canine leishmaniosis: an exploratory clinical trial.

Authors:  V Corpas-López; G Merino-Espinosa; C Acedo-Sánchez; V Díaz-Sáez; M C Navarro-Moll; F Morillas-Márquez; J Martín-Sánchez
Journal:  Vet Res Commun       Date:  2018-02-16       Impact factor: 2.459

4.  Characterisation of the ex vivo virulence of Leishmania infantum isolates from Phlebotomus perniciosus from an outbreak of human leishmaniosis in Madrid, Spain.

Authors:  Gustavo Domínguez-Bernal; Maribel Jiménez; Ricardo Molina; Lara Ordóñez-Gutiérrez; Abel Martínez-Rodrigo; Alicia Mas; Maria Teresa Cutuli; Javier Carrión
Journal:  Parasit Vectors       Date:  2014-11-07       Impact factor: 3.876

5.  New insights into experimental visceral leishmaniasis: Real-time in vivo imaging of Leishmania donovani virulence.

Authors:  Guilherme D Melo; Sophie Goyard; Hervé Lecoeur; Eline Rouault; Pascale Pescher; Laurence Fiette; Alexandre Boissonnas; Paola Minoprio; Thierry Lang
Journal:  PLoS Negl Trop Dis       Date:  2017-09-25

6.  Analysis of the Antigenic and Prophylactic Properties of the Leishmania Translation Initiation Factors eIF2 and eIF2B in Natural and Experimental Leishmaniasis.

Authors:  Esther Garde; Laura Ramírez; Laura Corvo; José C Solana; M Elena Martín; Víctor M González; Carlos Gómez-Nieto; Aldina Barral; Manoel Barral-Netto; José M Requena; Salvador Iborra; Manuel Soto
Journal:  Front Cell Infect Microbiol       Date:  2018-04-05       Impact factor: 5.293

7.  Coadministration of the Three Antigenic Leishmania infantum Poly (A) Binding Proteins as a DNA Vaccine Induces Protection against Leishmania major Infection in BALB/c Mice.

Authors:  Manuel Soto; Laura Corvo; Esther Garde; Laura Ramírez; Virginia Iniesta; Pedro Bonay; Carlos Gómez-Nieto; Víctor M González; M Elena Martín; Carlos Alonso; Eduardo A F Coelho; Aldina Barral; Manoel Barral-Netto; Salvador Iborra
Journal:  PLoS Negl Trop Dis       Date:  2015-05-08

8.  The protective immune response produced in dogs after primary vaccination with the LiESP/QA-21 vaccine (CaniLeish®) remains effective against an experimental challenge one year later.

Authors:  Virginie Martin; Ioannis Vouldoukis; Javier Moreno; David McGahie; Sylvie Gueguen; Anne-Marie Cuisinier
Journal:  Vet Res       Date:  2014-06-25       Impact factor: 3.683

9.  Improving the serodiagnosis of canine Leishmania infantum infection in geographical areas of Brazil with different disease prevalence.

Authors:  Laura Ramírez; Luana Dias de Moura; Natalia Lopes Fontoura Mateus; Milene Hoehr de Moraes; Leopoldo Fabrício Marçal do Nascimento; Nailson de Jesus Melo; Lucas Bezerra Taketa; Tatiana Catecati; Samuel G Huete; Karla Penichet; Eliane Mattos Piranda; Alessandra Gutierrez de Oliveira; Mario Steindel; Manoel Barral-Netto; Maria do Socorro Pires E Cruz; Aldina Barral; Manuel Soto
Journal:  Parasite Epidemiol Control       Date:  2019-11-21

10.  Establishment, optimisation and quantitation of a bioluminescent murine infection model of visceral leishmaniasis for systematic vaccine screening.

Authors:  Han Boon Ong; Simon Clare; Adam Jonathan Roberts; Mary Edythe Wilson; Gavin James Wright
Journal:  Sci Rep       Date:  2020-03-13       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.